Teleflex Incorporated (TFX) fair value analysis
S&P 500 · Updated 2026-09-07
Teleflex Incorporated is a medical device company that manufactures and distributes products used in critical care, anesthesia, surgery, and other clinical applications. The company operates globally, serving healthcare providers and patients across North America, Europe, and international markets.
Forward Fair Value verdict
UndervaluedBased on TickrTrends' weekly Forward Fair Value model, TFX is trading at a 10–25% discount to estimated fair value.
TFX currently ranks #56 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.
- Last price
- $141.56
- Sector
- Healthcare
- 12-month range
- $103.36–$140.48
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- Margin trend
- Stable
- Revenue growth
- Modest
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
What our data shows for TFX
- Our model validated 17 trailing price-to-earnings windows for TFX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $103.36–$140.48.
- The 14-day relative strength index sits at a neutral 51.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TFX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent TFX news
TickrTrends' derived news-sentiment signal for TFX is currently leaning positive, computed from recent coverage.
- Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push (insidermonkey.com, 2026-09-04)
TickrTrends take: Teleflex's reduction in forward guidance typically pressures valuations, yet the company's simultaneous expansion of its buyback program suggests management believes current price levels present an opportunity to return capital efficiently to shareholders. Given TickrTrends' undervalued assessment of the Healthcare sector company, investors focused on valuation metrics should monitor whether the guidance reduction reflects temporary headwinds or signals a more persistent challenge to earnings power. The interplay between reduced expectations and aggressive share repurchases will be critical in determining whether the undervalued designation holds as new financial results emerge. - Teleflex: Strong Company Undergoing Messy Transition, Hold (NYSE:TFX) (seekingalpha.com, 2026-08-23)
TickrTrends take: Teleflex's current undervalued status according to TickrTrends suggests the market may not be fully pricing in the company's underlying strength despite the operational challenges described in recent analysis. For valuation-focused investors, the key question is whether the current transition difficulties represent a temporary discount opportunity or a signal that execution risks warrant caution before the company proves it can navigate this period successfully. Monitoring how Teleflex progresses through this transition phase will be critical to determining whether the undervalued designation can eventually translate into value realization. - Teleflex Q2 Earnings Call Highlights (finance.yahoo.com, 2026-08-09)
TickrTrends take: Teleflex's Q2 earnings call provides an opportunity to assess whether the company's operational performance supports TickrTrends' current undervalued assessment in the Healthcare sector. Investors tracking valuation metrics should monitor management commentary on revenue trends, margin performance, and capital allocation to determine if current market pricing reflects the company's earnings power and growth trajectory. The earnings discussion may clarify whether recent market movements have created a genuine valuation opportunity or if concerns about the business warrant a closer examination of the undervaluation thesis.
What people are saying
Follow the TFX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — TickrTrends' derived indicators for TFX showed a shift in valuation assessment this week, with the DCF cross-check band moving from overvalued to fairly valued. Despite this adjustment in the DCF cross-check band, the overall current valuation verdict remains undervalued, indicating that other valuation indicators in the analysis continue to support a below-intrinsic-value assessment for the Healthcare sector company.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TFX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), TFX is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TFX's TickrTrends verdict?
TFX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TFX compare to other Healthcare stocks?
TFX ranks #56 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is TFX overbought or oversold?
TFX's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
TFX vs A · TFX vs BDX · TFX vs ENSG · TFX vs HCA · TFX vs INVA